{
    "clinical_study": {
        "@rank": "117837", 
        "arm_group": {
            "arm_group_label": "Study Drug- ALXN1007- Open label study", 
            "arm_group_type": "Experimental", 
            "description": "Study Drug- ALXN1007"
        }, 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to evaluate the safety and tolerability of intravenous\n      (IV) ALXN1007 in persistently antiphospholipid (aPL)-positive patients with at least 1 of\n      the following non-criteria manifestations of APS: aPL-nephropathy, skin ulcers and/or\n      thrombocytopenia."
        }, 
        "brief_title": "Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Antiphospholipid (aPL)-Positive", 
        "condition_browse": {
            "mesh_term": "Antiphospholipid Syndrome"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Patients with a persistent and clinically significant aPL profile\n\n        Patients with at least 1 of the following non-criteria manifestations of APS:\n\n          1. aPL-nephropathy (diagnosed by kidney biopsy within 12 months of Screening) confirmed\n             based on the updated APS Classification Criteria recommendations, and urine protein\n             to creatinine ratio > 1.0 at the time of the Screening visit and/or\n\n          2. Skin ulcers (non-infected livedoid vasculitis-like skin ulcer and/or large skin\n             ulceration resembling pyoderma gangrenosum) for at least 4 weeks prior to the\n             Screening visit, diagnosed by physical examination, and/or\n\n          3. Persistent active thrombocytopenia (diagnosed by platelet counts <100 x 103/\u03bcL and\n             \u226520 x 103/\u03bcL [SI: <100 x 109/L and \u2265 20 x 109/L]) and confirmed at the time of\n             screening (at least 4 weeks after previous test) based on the updated APS\n             Classification Criteria recommendations Patients and spouse/partner who is of\n             childbearing potential must be using highly effective contraception consisting of 2\n             forms of birth control (at least 1 of which must be a barrier method) starting at\n             Screening and continuing through the entire study.\n\n        Patients with aPL-nephropathy must be receiving or agree to initiate an ACE inhibitor or\n        angiotensin receptor blocker at least 4 weeks prior to initiation of ALXN1007 treatment;\n        unless patient is documented to be intolerant. Patients receiving oral corticosteroids\n        must be on a stable dose of \u2264 10 mg/day of prednisone or equivalent dose of another\n        corticosteroid preparation for at least 4 weeks prior to the first dose of ALXN1007.\n        Patients receiving immunosuppressive medications (including but not limited to\n        methotrexate, hydroxychloroquine, azathioprine, cyclosporine and mycophenolate mofetil)\n        must be on a stable dose for at least 4 weeks prior to the first dose of ALXN1007.\n        Patients receiving oral anticoagulants or antiplatelet agents (including but not limited\n        to aspirin) must be on stable doses for at least 4 weeks prior to first dose of ALXN1007.\n\n        Patients must be willing and able to give written informed consent and to comply with all\n        study visits and procedures.\n\n        Exclusion Criteria:\n\n        Patients meeting the ACR classification criteria for systemic lupus erythematosus,\n        systemic sclerosis or other systemic autoimmune diseases other than Primary APS.\n\n        Patients experiencing an acute thrombosis or a Major Adverse Vascular Event (MAVE) within\n        12 weeks prior to first administration of ALXN1007.\n\n        Patients with skin ulcers from causes other than aPL or who are positive for DVT or venous\n        insufficiency at Screening. Patients with renal function status requiring chronic dialysis\n        (defined as dialysis on a regular basis as renal replacement therapy). Patients with\n        unresolved meningococcal disease or with known active bacterial, viral, fungal,\n        mycobacterial or other infection. Patients that have received IVIg treatment within 4\n        weeks prior to first dose of ALXN1007. Patients that have received a course of rituximab\n        (RITUXAN\u00ae) therapy within 12 months prior to first dose of ALXN1007 or have evidence of\n        persistent depletion of the targeted lymphocyte population. Women who are pregnant or\n        nursing."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02128269", 
            "org_study_id": "ALXN1007-APS-201", 
            "secondary_id": "2013-003588-73"
        }, 
        "intervention": {
            "arm_group_label": "Study Drug- ALXN1007- Open label study", 
            "description": "10 mg/kg IV q 2 weeks x 12 doses", 
            "intervention_name": "Study Drug- ALXN1007", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Antiphospholipid (aPL)-positive", 
            "Antiphospholid syndrome (APS)"
        ], 
        "lastchanged_date": "April 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Hospital for Special Surgery"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Alexion Pharmaceuticals, clinicaltrials@alxn.com"
                }, 
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals"
                }, 
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77555"
                    }, 
                    "name": "University of Texas Medical Branch"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals"
                }, 
                "facility": {
                    "address": {
                        "city": "Vandoeuvre les Nancy", 
                        "country": "France", 
                        "state": "Meurthe et Moselle", 
                        "zip": "54511"
                    }, 
                    "name": "H\u00f4pital de Brabois Adultes"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "clinicaltrials@alxn.com", 
                    "last_name": "Alexion Pharmaceuticals"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "state": "Greater London", 
                        "zip": "NW12PG"
                    }, 
                    "name": "University College London Hospitals"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome", 
        "other_outcome": {
            "description": "Urine protein to creatinine ratio for patients with aPL-nephropathy. Manual measurement of ulcer area and objective analysis of  digital photographs for patients with skin ulcers.\nPlatelet count for patients with thrombocytopenia.", 
            "measure": "To assess the effect of ALXN1007 on aPL-nephropathy, skin ulcers and thrombocytopenia", 
            "safety_issue": "No", 
            "time_frame": "Treatment Period (24 weeks) and Follow-up Period (12 weeks)."
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "France: ANSM"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Safety will be assessed based on the incidence and severity of treatment emergent adverse events and serious adverse events.  Incidence of clinical laboratory abnormalities and changes from baseline through study completion in vital signs, physical examinations, ECGs and laboratory tests will also be evaluated", 
            "measure": "To evaluate the safety and tolerability of intravenous (IV) ALXN1007 in persistently antiphospholipid (aPL)-positive patients with at least 1 of the following non-criteria manifestations of APS: aPL-nephropathy, skin ulcers and/or thrombocytopenia", 
            "safety_issue": "Yes", 
            "time_frame": "Treatment Period (24 weeks) and Follow-up Period (12 weeks)."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02128269"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Estimates of PK parameters will include, at a minimum, time to maximum observed plasma concentration (tmax), maximum observed plasma concentration (Cmax), and total body clearance (CLR).", 
                "measure": "To evaluate the pharmacokinetic (PK) parameters of IV ALXN1007.", 
                "safety_issue": "No", 
                "time_frame": "Treatment Period (24 weeks) and Follow-up Period (12 weeks)."
            }, 
            {
                "description": "The PD endpoints will include changes from baseline in several complement protein levels and assessment of effect on terminal complement activity through Week 24.", 
                "measure": "To evaluate the pharmacodynamic (PD) effects of IV ALXN1007.", 
                "safety_issue": "No", 
                "time_frame": "Treatment Period (24 weeks) and Follow-up Period (12 weeks)."
            }
        ], 
        "source": "Alexion Pharmaceuticals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Alexion Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}